NMRA · Insider Trading
Neumora Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by NMRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | Michael Lee Milligan | See Remarks | A | +175,000 deriv. | — |
| 2026-08-21 | Jason Duncan | See Remarks | A | +375,000 deriv. | — |
| 2026-08-21 | Paul L Berns | See Remarks | A | +500,000 deriv. | — |
| 2026-08-21 | Daljit Singh Aurora | See Remarks | MIXED | — | −$143.20K |
| 2026-08-21 | Joshua Pinto | President & CEO | A | +500,000 deriv. | — |
| 2026-08-19 | Daljit Singh Aurora | See Remarks | MIXED | −34,020 | −$256.17K |
| 2026-05-29 | David Piacquad | Director | A | +80,000 deriv. | — |
| 2026-05-29 | Matthew K Fust | Director | A | +80,000 deriv. | — |
| 2026-05-29 | Alaa Halawa | Director | A | +80,000 deriv. | — |
| 2026-05-29 | Maykin Ho | Director | A | +80,000 deriv. | — |
| 2026-05-29 | Kristina Burow | Director | A | +80,000 deriv. | — |
| 2026-02-19 | Daljit Singh Aurora | See Remarks | Sell | −6,165 | −$21.92K |
| 2026-02-19 | Joshua Pinto | President | Sell | −5,967 | −$21.09K |
| 2026-02-19 | Michael Lee Milligan | See Remarks | Sell | −1,436 | −$5.12K |
| 2026-02-19 | Paul L Berns | See Remarks | Sell | −9,819 | −$34.46K |
| 2026-01-09 | Daljit Singh Aurora | See Remarks | A | +750,000 deriv. | — |
| 2026-01-09 | Jason Duncan | See Remarks | A | +750,000 deriv. | — |
| 2026-01-09 | Paul L Berns | See Remarks | A | +1,650,000 deriv. | — |
| 2026-01-09 | Michael Lee Milligan | See Remarks | A | +350,000 deriv. | — |
| 2026-01-09 | Joshua Pinto | President | A | +1,200,000 deriv. | — |
| 2025-11-13 | Daljit Singh Aurora | See Remarks | Sell | −114,703 | −$307.03K |
| 2025-10-29 | Kristina Burow | Director | Buy | +1,915,700 | +$5.00M |
| 2025-10-29 | Keith Crandell | 10%+ Owner | Buy | +13,409,900 | +$35.00M |
| 2025-10-29 | ARCH Venture Fund X, L.P. | 10%+ Owner | Buy | +19,157,000 | +$50.00M |
| 2025-05-30 | Jason Duncan | See Remarks | MIXED | — | — |
| 2025-05-30 | David Piacquad | Director | MIXED | +80,000 deriv. | — |
| 2025-05-30 | Matthew K Fust | Director | MIXED | +80,000 deriv. | — |
| 2025-05-30 | Joshua Pinto | President | MIXED | — | — |
| 2025-05-30 | Paul L Berns | See Remarks | MIXED | — | — |
| 2025-05-30 | Alaa Halawa | Director | MIXED | +80,000 deriv. | — |
| 2025-05-30 | Daljit Singh Aurora | See Remarks | MIXED | — | — |
| 2025-05-30 | Michael Lee Milligan | See Remarks | MIXED | — | — |
| 2025-05-30 | Maykin Ho | Director | MIXED | +80,000 deriv. | — |
| 2025-05-30 | Kristina Burow | Director | MIXED | +80,000 deriv. | — |
| 2025-05-23 | Joshua Pinto | President | G | — | — |
| 2025-02-20 | Robert A. Lenz | Head of R&D | Sell | −5,614 | −$9.38K |
| 2025-02-20 | Daljit Singh Aurora | Chief Strategy Officer | Sell | −8,565 | −$14.35K |
| 2025-02-20 | Michael Lee Milligan | See Remarks | Sell | −1,978 | −$3.35K |
| 2025-02-20 | Joshua Pinto | President | Sell | −8,048 | −$13.48K |
| 2025-02-20 | Paul L Berns | See Remarks | Sell | −13,871 | −$23.47K |
| 2025-02-18 | Alaa Halawa | Director | MIXED | — | — |
| 2025-02-18 | Paul L Berns | See Remarks | MIXED | +2,000,000 deriv. | — |
| 2025-02-18 | Jason Duncan | See Remarks | MIXED | +500,000 deriv. | — |
| 2025-02-18 | Kristina Burow | Director | MIXED | — | — |
| 2025-02-18 | Daljit Singh Aurora | See Remarks | MIXED | +1,000,000 deriv. | — |
| 2025-02-18 | David Piacquad | Director | MIXED | — | — |
| 2025-02-18 | Maykin Ho | Director | MIXED | — | — |
| 2025-02-18 | Michael Lee Milligan | See Remarks | MIXED | +400,000 deriv. | — |
| 2025-02-18 | Robert A. Lenz | Head of R&D | MIXED | — | — |
| 2025-02-18 | Joshua Pinto | President | MIXED | +3,000,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kristina Burow | Director | 11,934,475 | $4.69M |
| Paul L Berns | See Remarks | 7,528,282 | $2.96M |
| Keith Crandell | 10%+ Owner | 6,046,907 | $2.38M |
| ARCH Venture Fund X, L.P. | 10%+ Owner | 6,046,907 | $2.38M |
| Robert A. Lenz | Head of R&D | 309,092 | $121.44K |
| Joshua Pinto | President & CEO | 209,950 | $82.49K |
| Daljit Singh Aurora | See Remarks | 70,435 | $27.67K |
| Matthew K Fust | Director | 27,839 | $10.94K |
| Michael Lee Milligan | See Remarks | 21,034 | $8.26K |
| David Piacquad | Director | 20,100 | $7.90K |
| Maykin Ho | Director | 20,100 | $7.90K |
| Alaa Halawa | Director | 20,100 | $7.90K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NMRA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.